Skip to main content
Top
Literature
1.
go back to reference Zuelzer WW (1964) Myelokathexis: a new form of chronic granulocytopenia. New Eng J Med 270:699–704CrossRef Zuelzer WW (1964) Myelokathexis: a new form of chronic granulocytopenia. New Eng J Med 270:699–704CrossRef
2.
go back to reference Lagane B, Chow KY, Balabanian K, Levoye A, Harriague J, Planchenault T et al (2008) CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 112:34–44CrossRef Lagane B, Chow KY, Balabanian K, Levoye A, Harriague J, Planchenault T et al (2008) CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 112:34–44CrossRef
3.
go back to reference Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O et al (2005) WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 105:2449–2457CrossRef Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O et al (2005) WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 105:2449–2457CrossRef
4.
go back to reference McDermott DH, Gao JL, Liu Q, Siwicki M, Martens C, Jacobs P et al (2015) Chromothriptic cure of WHIM syndrome. Cell 160:686–699CrossRef McDermott DH, Gao JL, Liu Q, Siwicki M, Martens C, Jacobs P et al (2015) Chromothriptic cure of WHIM syndrome. Cell 160:686–699CrossRef
5.
go back to reference McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E et al (2019) Plerixafor for the treatment of WHIM syndrome. New Eng J Med 380:163–170CrossRef McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E et al (2019) Plerixafor for the treatment of WHIM syndrome. New Eng J Med 380:163–170CrossRef
Metadata
Title
Morphology As a Guide to the Diagnosis of a Rare Cause of Neutropenia
Authors
Dhaarani Jayaraman
Greeshma Rajeev
Sri Gayathri Shanmugam
Febe Renjitha Suman
Publication date
01-10-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01288-7

Other articles of this Issue 4/2020

Indian Journal of Hematology and Blood Transfusion 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine